Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

A group of leading African researchers trying to develop effective vaccines against HIV is trying to figure out how to ...

Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...

A Lancet study shows promising results for an annual HIV prevention injection, lenacapavir. In Stage 1 trials, 40 HIV-negative participants had no significant side effects ...

An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

The man’s case didn’t give rise to any widespread variant, but it gave Gupta, with his HIV evolution background, the idea ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people living with HIV and outlines future research priorities.

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

Yearly doses could reduce barriers people face to taking preventative HIV medication, researchers said. An annual jab to ...